- Detailed EXPLANATION of the test performed and recommendations to be followed.
- SUMMARY TABLE presenting the metabolic areas analysed and the results from the DNA analysis, providing a quick overview of an individual's overall health status and highlighting any potential issues.
- BIBLIOGRAPHY providing scientific references for the test.

COLOURS USED

It indicates that the variants identified in the analysis not unfavourably alter the enzymatic activity of the proteins they encode and/or the risk associated with certain diseases.

It indicates that the variants identified in the analysis slightly unfavourably alter enzyme activity and/or the risk associated with certain disorders or diseases.

It indicates that the variants identified in the analysis alter enzyme activity in a particularly unfavourable way, resulting in an increased risk of developing certain disorders or associated diseases.

The results shown, as well as the considerations and explanations contained in the following pages of this booklet, should not be regarded as a medical diagnosis. It is important to bear in mind that the genetic information is only a part of the total information needed to gain a complete picture of a person's state of health, and the data reported here is therefore a tool available to the treating physician to formulate a correct assessment of the patient's physiological state and suggest an appropriate personalised treatment.

INTRODUCTION

The **MacroMatch DNA test** is an advanced genetic analysis designed to provide detailed insights into an individual's metabolism of macronutrients and caffeine. By analysing your genetic profile, this test identifies specific DNA variants that influence how your body processes **carbohydrates, fats, proteins, and caffeine**, enabling a **personalized approach** to nutrition and lifestyle.

The analysis focuses on four key aspects of metabolism:

1. **Carbohydrate Metabolism** – Determines how efficiently the body metabolizes and utilizes carbohydrates, influencing **glycaemic response** and the risk of energy imbalances.
2. **Lipid Metabolism** – Assesses genetic predisposition to **fat accumulation or oxidation**, affecting weight control and cardiovascular health.
3. **Protein Metabolism** – Evaluates how efficiently the body **utilizes essential amino acids**, crucial for muscle synthesis and recovery.
4. **Caffeine Metabolism** – Examines **caffeine processing speed** and its impact on cognitive function, sleep, and blood pressure.

The **MacroMatch test** is conducted using state-of-the-art technology to ensure **accurate and reliable results**. The insights gained can help optimize **nutrition, enhance physical performance, and reduce potential health risks** based on individual metabolism.

What Are Macronutrients and Why Consider Caffeine?

Macronutrients ("macros") are the primary components of our diet, providing the **energy** required for the body to function. Since **each person metabolizes these nutrients differently**, the **MacroMatch test** helps determine the most effective macronutrient ratios for optimal health and performance.

- **Carbohydrates** serve as the **main energy source**. They are converted into glucose to fuel the **brain, muscles, and organs**. However, some individuals metabolize carbohydrates less efficiently, which can impact **weight regulation and energy levels**.
- **Fats** are **essential for cell health, hormone production, and vitamin absorption**. However, not all fats are equal—some promote **health and metabolism**, while others may increase the risk of metabolic disorders.
- **Proteins** are the **building blocks** of the body, necessary for **muscle growth, cellular repair, and the production of enzymes and hormones**. The optimal protein intake varies based on **individual genetics**.
- **Caffeine** is **not a macronutrient**, but it **affects metabolism and energy levels**. Your DNA determines whether you are a **fast or slow metabolizer**, influencing **caffeine sensitivity** and its effects on sleep, cognition, and cardiovascular health.

For a **comprehensive interpretation of your results** and **personalized recommendations**, we recommend consulting a **nutritionist or a specialist in nutrigenetics**.

1. CARBOHYDRATE METABOLISM TEST

Genetic analysis of the PPARG, KCNJ11, and TCF7L2 genes focuses on evaluating an individual's predisposition to carbohydrate metabolism and the risk of developing metabolic disorders, such as insulin resistance and type 2 diabetes.

- **PPARG (Peroxisome Proliferator-Activated Receptor Gamma)**: This gene regulates lipid and carbohydrate metabolism, influencing insulin sensitivity. Certain genetic variants are linked to an increased risk of insulin resistance and obesity.
- **KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11)**: This gene encodes a protein that helps regulate insulin secretion from pancreatic beta cells. Mutations in KCNJ11 may affect glycaemic responses and contribute to the risk of diabetes.
- **TCF7L2 (Transcription Factor 7 Like 2)**: This gene plays a pivotal role in regulating insulin secretion and glucose sensitivity. Some genetic variants in TCF7L2 are among the strongest known genetic risk factors for type 2 diabetes.

By analysing these genes, it becomes possible to identify genetic predispositions and adopt personalized strategies to improve carbohydrate metabolism through diet and lifestyle changes.

YOUR RESULT:

Lab ID	Gene	Allelic variants	Genotype		Result
CARBOHYDRATE METABOLISM					
GTS009	PPARG	G	G	G	FAVOURABLE
(peroxisome proliferator activated receptor-2 - PPAR-γ2)		C			
WHAT YOUR GENETICS SAY					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Lab ID	Gene	Allelic variants	Genotype		Result
CARBOHYDRATE METABOLISM					
GTS010	KCNJ11	C	C	C	FAVOURABLE
(potassium imwardly rectifying channel subfamilyJ member11)		T			
WHAT YOUR GENETICS SAY					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Lab ID	Gene	Allelic variants	Genotype		Result
CARBOHYDRATE METABOLISM					
GTS040	TCFL7L2	C	C	C	FAVOURABLE
(Transcription Factor 7- Like2)		T			
WHAT YOUR GENETICS SAY					
					
There is a FAVOURABLE genetic profile for the analyzed gene.					

EFFECTS OF UNFAVOURABLE VARIANTS for the PPARG, KCNJ11 and TCF7L2 genes

Unfavourable genetic variants in the PPARG, KCNJ11, and TCF7L2 genes can negatively affect carbohydrate metabolism, increasing the risk of developing metabolic disorders. The effects of these variants on carbohydrate metabolism and their association with conditions like insulin resistance and type 2 diabetes are as follows:

- **PPARG (Peroxisome Proliferator-Activated Receptor Gamma):**
  - Decreased insulin sensitivity, heightening the risk of insulin resistance.
  - Greater tendency to accumulate body fat, particularly in the abdominal region.
  - Elevated risk of obesity and type 2 diabetes, especially when combined with a diet high in saturated fats.
  - Reduced effectiveness of PPARG agonist medications (e.g., thiazolidinediones used for diabetes treatment).
- **KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11):**
  - Altered potassium channel function in pancreatic beta cells, leading to impaired insulin secretion.
  - Reduced pancreatic ability to adjust to fluctuations in blood glucose levels, raising the risk of hyperglycaemia.
  - Increased susceptibility to type 2 diabetes, particularly among individuals with a higher BMI.
  - Potential reduction in the effectiveness of drugs that target potassium channels, such as sulfonylureas (common anti-diabetic medications).
- **TCF7L2 (Transcription Factor 7 Like 2):**
  - Disrupted regulation of insulin secretion from pancreatic beta cells.
  - Increased risk of insulin resistance and reduced capacity to manage blood glucose.
  - Higher risk of developing type 2 diabetes, regardless of factors such as body weight.
  - Impaired insulin response following carbohydrate consumption, leading to higher glucose levels post-meal.
  - Decreased efficacy of certain medications like GLP-1 agonists, which stimulate insulin secretion.

In conclusion, these genetic variants can predispose individuals to disorders related to carbohydrate metabolism. However, their impact is influenced by environmental factors like diet and physical activity. Understanding these genetic predispositions enables the development of personalized strategies to prevent or manage insulin resistance and type 2 diabetes.

RECOMMENDED SOLUTIONS:

To counteract the effects of unfavourable variants in the PPARG, KCNJ11, and TCF7L2 genes, the following dietary and lifestyle changes, as well as therapeutic options, are recommended:

- **PPARG (Peroxisome Proliferator-Activated Receptor Gamma)**

Goal: Improve insulin sensitivity and reduce fat accumulation.

1. **Dietary Recommendations:**
    - Limit saturated fats (e.g., red meat, whole milk, fried foods), which can worsen insulin resistance.
    - Increase unsaturated fats (e.g., olive oil, oily fish, nuts) to support PPARG function.
    - Follow a low glycaemic index diet with whole grains, vegetables, and lean proteins to stabilize blood glucose.
    - Consume more soluble fibre (e.g., oats, legumes, flaxseeds) to aid in carbohydrate absorption.
2. **Lifestyle Recommendations:**
    - Engage in regular physical activity, with a focus on resistance training (e.g., weightlifting) and aerobic exercise (e.g., brisk walking, swimming) to enhance insulin sensitivity.
    - Monitor body weight, as excess weight can amplify the effects of the unfavourable variant.
3. **Potential Therapeutic Strategies:**
    - In cases of diabetes or insulin resistance, healthcare providers may consider insulin-sensitizing medications such as metformin or thiazolidinediones.

- **KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11)**

Goal: Support pancreatic function and enhance insulin secretion regulation.

1. **Dietary Recommendations:**
    - Distribute carbohydrate intake throughout the day in smaller, more frequent meals to avoid glycaemic spikes.
    - Avoid simple sugars (e.g., sweets, sugary drinks) that can overload the pancreas.
    - Increase intake of magnesium and potassium (e.g., dried fruits, leafy greens, bananas) to support the ion channels involved in insulin secretion.
2. **Lifestyle Recommendations:**
    - Engage in regular physical activity, particularly exercises that improve insulin sensitivity (e.g., high-intensity aerobic training).
    - Manage stress levels, as chronic high cortisol can negatively affect pancreatic function.
3. **Potential Therapeutic Strategies:**
    - In cases of diabetes, a healthcare provider may recommend medications that enhance insulin secretion, such as sulfonylureas or DPP-4 inhibitors.

- **TCF7L2 (Transcription Factor 7 Like 2)**

Goal: Improve insulin secretion and optimize blood glucose response.

1. **Dietary Recommendations:**
    - Follow a low glycaemic load diet, balancing complex carbohydrates, proteins, and healthy fats to avoid blood sugar surges.
    - Avoid refined carbohydrates (e.g., white bread, sweets) that may worsen impaired insulin secretion.
    - Increase consumption of polyphenols and antioxidants (e.g., green tea, berries, bitter cocoa) to protect pancreatic cells from oxidative damage.
    - Include legumes and high-fibre foods to slow glucose absorption.
2. **Lifestyle Recommendations:**
    - Incorporate regular physical activity, which helps compensate for reduced insulin secretion.
    - Maintain a healthy body weight to improve overall glycaemic management.

3. **Potential Therapeutic Strategies:**
    - In cases of diabetes, doctors may consider GLP-1 agonists or DPP-4 inhibitors to better stimulate insulin secretion.
    - Regular blood glucose monitoring is recommended, even if symptoms are not evident.

In summary, if one has unfavourable variants of these genes, adopting a healthy lifestyle and a targeted diet can significantly reduce the risk of developing metabolic disorders. The personalised approach, based on genetic results, can optimise carbohydrate metabolism, and improve long-term health.

Carbohydrate sources:

Carbohydrates are primarily found in the following food groups:

- **Cereals and Grains:** Bread, pasta, rice, spelt, barley, oats, millet, quinoa, rye, maize, polenta, couscous, crackers, and cereal flakes.
- **Legumes:** Beans, lentils, chickpeas, peas, broad beans, soy, and lupins.
- **Tubers and Roots:** Potatoes, cassava, yam, Jerusalem artichoke, and yuca.
- **Fruits:** Bananas, apples, pears, grapes, dates, figs, mangoes, pineapples, cherries, apricots, peaches, kiwis, oranges, tangerines, strawberries, blueberries, and raspberries.
- **Vegetables:** Carrots, beets, squash, onions, tomatoes, and peppers.
- **Dairy Products:** Milk, yogurt, and fresh cheeses such as cottage cheese, which contain lactose.
- **Sweets and Processed Products:** White and brown sugar, honey, syrups, jams, cakes, biscuits, snacks, sugary cereals, milk chocolate, ice cream, and candy. Additionally, sugary drinks like fruit juices, soft drinks, sweetened tea, coffee, and energy drinks are rich in simple carbohydrates.

Carefully managing carbohydrate intake from these sources can play a key role in optimizing carbohydrate metabolism and reducing the risk of metabolic disorders.

2. LIPID METABOLISM TEST

Genetic analysis of the **APOA1**, **APOC3**, **CETP**, and **LDLR** genes provides essential insights into lipid metabolism and the potential risk for dyslipidaemia and cardiovascular disease:

- **APOA1 (Apolipoprotein A1)**: This gene plays a key role in reverse cholesterol transport and is a major component of HDL ("good" cholesterol). Genetic variants can influence HDL levels and affect cardiovascular risk.
- **APOC3 (Apolipoprotein C3)**: APOC3 regulates triglyceride metabolism, influencing the likelihood of hypertriglyceridemia and related conditions such as metabolic syndrome.
- **CETP (Cholesteryl Ester Transfer Protein)**: This gene governs the transfer of cholesterol between lipoproteins. Certain genetic variants can impact levels of HDL and LDL cholesterol, influencing overall cardiovascular health.
- **LDLR (Low-Density Lipoprotein Receptor)**: LDLR is responsible for removing LDL ("bad" cholesterol) from the bloodstream. Mutations in this gene can elevate the risk of familial hypercholesterolemia and the development of atherosclerosis.

By analysing these key genes, we can identify individual genetic predispositions and help create personalized strategies for managing cardiovascular risk, incorporating lifestyle changes like diet and exercise, along with targeted medical interventions if necessary.

YOUR RESULT:

Lab ID	Gene	Allelic variants	Genotype		Result
LIPID METABOLISM					
GTS036	APOA1	T	T	T	FAVOURABLE
(Apolipoprotein isoform A1)		C			
WHAT YOUR GENETICS SAY					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Lab ID	Gene	Allelic variants	Genotype		Result
LIPID METABOLISM					
GTS037	APOC3	C	C	C	FAVOURABLE
(Apolipoprotein isoform C3)		G			
WHAT YOUR GENETICS SAY					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Lab ID	Gene	Allelic variants	Genotype		Result
LIPID METABOLISM					
GTS038	CETP	A	A	A	FAVOURABLE
(Cholesterol ester transfer protein)		G			
WHAT YOUR GENETICS SAY					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Lab ID	Gene	Allelic variants	Genotype		Result
LIPID METABOLISM					
GTS039	LDLR	G	G	G	FAVOURABLE
(Low-Density Lipoprotein Receptor)		T			
WHAT YOUR GENETICS SAY					
					
There is a FAVOURABLE genetic profile for the analyzed gene.					

EFFECTS OF UNFAVORABLE VARIANTS IN THE APOA1, APOC3, CETP, AND LDLR GENES

Genetic variations in the **APOA1, APOC3, CETP, and LDLR** genes can impact lipid metabolism, potentially increasing the risk of cardiovascular disease. Understanding these genetic factors allows for proactive measures to improve heart health. Below are the effects of unfavourable variants in each gene:

- ***APOA1 (Apolipoprotein A1)***

  - **Effect of Unfavourable Variants**: Some genetic variants reduce the production or functionality of apolipoprotein A1, leading to lower levels of HDL cholesterol ("good" cholesterol).
  - **Potential Consequences**: Increased risk of atherosclerosis and cardiovascular disease due to a reduced ability to clear excess cholesterol from tissues.

- ***APOC3 (Apolipoprotein C3)***

  - **Effect of Unfavourable Variants**: Certain genetic mutations inhibit the breakdown of triglycerides, causing their accumulation in the bloodstream.
  - **Potential Consequences**: Higher risk of **hypertriglyceridemia**, fatty liver disease, insulin resistance, and an increased likelihood of cardiovascular disease.

- ***CETP (Cholesteryl Ester Transfer Protein)***

  - **Effect of Unfavourable Variants**: Increased CETP activity promotes the transfer of cholesterol from HDL to LDL, lowering "good" HDL levels while raising "bad" LDL cholesterol.
  - **Potential Consequences**: An unfavourable lipid profile, characterized by lower protective HDL cholesterol and higher LDL cholesterol, increasing the risk of cardiovascular diseases.

- ***LDLR (Low-Density Lipoprotein Receptor)***

  - **Effect of Unfavourable Variants**: Mutations in the **LDLR** gene impair the liver's ability to remove LDL cholesterol from the blood efficiently.
  - **Potential Consequences**: Increased LDL cholesterol levels from an early age, leading to **familial hypercholesterolemia**, a significantly higher risk of **atherosclerosis**, and early onset coronary artery disease.

By identifying these genetic predispositions, individuals can take targeted preventive actions through **dietary adjustments, lifestyle changes, and, if necessary, medical interventions** to mitigate cardiovascular risks.

RECOMMENDED SOLUTIONS:

If you have unfavourable genetic variants in the **APOA1, APOC3, CETP, or LDLR** genes, adopting targeted strategies can significantly lower your risk of metabolic and cardiovascular disorders. Below are specific recommendations based on each gene:

- APOA1 (Low HDL Levels – "Good" Cholesterol Deficiency)

1. Dietary Adjustments:

- Increase consumption of **monounsaturated and polyunsaturated fats** (e.g., olive oil, avocados, nuts, and fatty fish).
- Avoid **trans fats** (found in processed foods) and limit **saturated fats**, which can further lower HDL levels.
- Eat **fibre-rich foods** (e.g., whole grains, legumes, fruits, and vegetables) to support lipid metabolism.

2. Lifestyle Modifications:

- Engage in **aerobic exercise** (e.g., running, swimming, and cycling) to naturally boost HDL cholesterol.
- Avoid **smoking and excessive alcohol consumption**, both of which lower HDL levels.

3. Medical Support:

- In some cases, **niacin (vitamin B3)** or other lipid-modifying drugs may be prescribed to help raise HDL levels.

- APOC3 (Elevated Triglycerides – Risk of Hypertriglyceridemia)

1. Dietary Adjustments:

- Reduce intake of **refined carbohydrates and added sugars**, which contribute to high triglyceride levels.
- Limit **alcohol consumption**, as it significantly raises blood triglycerides.
- Opt for **lean proteins and healthy fats** (e.g., omega-3 from fish, flaxseeds, and walnuts).

2. Lifestyle Modifications:

- Increase **physical activity**, particularly aerobic exercises like jogging and cycling, which help lower triglycerides.
- Maintain a **healthy body weight**, as excess weight contributes to hypertriglyceridemia.

3. Medical Support:

- If triglyceride levels are very high, **omega-3 supplements, fibrates, or statins** may be prescribed.

- **CETP (Low HDL and High LDL – Unfavourable Cholesterol Transfer)**

1. Dietary Adjustments:

- Follow a **heart-healthy diet** rich in **healthy fats** (olive oil, nuts, and fatty fish).
- Increase intake of **soluble fibre** (found in oats, legumes, and apples) to help reduce LDL cholesterol absorption.
- Avoid **processed foods and fried foods**, which contribute to an unhealthy lipid profile.

2. Lifestyle Modifications:

- Engage in **regular exercise** to improve cholesterol levels.
- Manage **stress levels**, as chronic stress can negatively impact cholesterol metabolism.

3. Medical Support:

- Certain **CETP inhibitors** (still under study) and **statins** may be recommended to improve lipid balance.

- LDLR (High LDL Cholesterol – Risk of Familial Hypercholesterolemia)

1. Dietary Adjustments:

- Reduce consumption of **saturated fats and dietary cholesterol** (e.g., red meat, full-fat dairy, and fried foods).
- Increase intake of **plant sterols** (found in nuts, legumes, and vegetable oils) to help block cholesterol absorption.
- Include **omega-3-rich foods** (e.g., fatty fish, flaxseeds, and walnuts) to lower inflammation and support heart health.

2. Lifestyle Modifications:

- Avoid **smoking and excessive alcohol consumption**, both of which impair LDL receptor function.
- Engage in **aerobic exercise**, such as brisk walking and cycling, to enhance cholesterol metabolism.

3. Medical Support

- If LDL cholesterol is significantly high, **statins, ezetimibe, or PCSK9 inhibitors** may be prescribed to lower cardiovascular risk.

By implementing these strategies and undergoing regular **medical monitoring**, individuals can help counteract the effects of unfavourable genetic variants and protect against cardiovascular disease.

Lipid sources:

Lipids come from various food sources and are classified based on their nutritional value:

1. Healthy Fats (Beneficial for Heart Health)

- **Monounsaturated Fats**: Found in **olive oil, avocados, nuts (almonds, walnuts, cashews), and seeds (flax, sesame, sunflower)**.
- **Polyunsaturated Fats (Omega-3 & Omega-6)**:
  - **Omega-3**: Present in **fatty fish (salmon, mackerel, tuna, sardines, herring), flaxseeds, chia seeds, and walnuts**.
  - **Omega-6**: Found in **vegetable oils (sunflower, soybean, corn oil)**.

2. Saturated Fats (Should Be Moderated)

- Found in **red meat (beef, lamb, pork), full-fat dairy (butter, cheese, whole milk), coconut oil, palm oil, dark chocolate, and egg yolks**.

3. Trans Fats (Should Be Avoided Completely)

- Found in **margarine, hydrogenated vegetable oils, processed snacks (biscuits, crackers, chips), fast food, and commercial baked goods**.

Key Takeaway: Prioritizing unsaturated fats, limiting saturated fats, and eliminating trans fats is crucial for maintaining a healthy lipid profile and reducing cardiovascular risk.

3. TESTS FOR PROTEIN METABOLISM

Genetic analysis of the ACTN3, FTO, and MTHFR genes provides valuable insights into protein metabolism, helping to understand how the body utilizes amino acids, responds to protein intake, and impacts body composition and physical performance.

- **ACTN3**: Codes for a muscle protein involved in fast-twitch fibers, influencing muscle strength and power. Genetic variants can predispose individuals to either explosive strength or endurance capabilities.
- **FTO**: Linked to appetite regulation and metabolism, it affects protein synthesis and the ability to maintain lean mass, which plays a role in weight management.
- **MTHFR**: Encodes a protein essential for homocysteine and folate metabolism. The activity of MTHFR is involved in amino acid synthesis and DNA repair, both critical for protein production and maintenance.

This analysis allows for a personalized approach to protein intake and training, tailored to genetic predispositions, enhancing recovery and overall physical performance.

YOUR RESULT:

Lab ID	Gene	Allelic variants	Genotype		Result
Protein metabolism					
GTS026	ACTN3	C	C	C	FAVOURABLE
(alfa-actinina-3)		T			
WHAT YOUR GENETICS SAY					
					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Lab ID	Gene	Allelic variants	Genotype		Result
Protein metabolism					
GTS007	FTO	T	T	T	FAVOURABLE
(Fat Mass and Obesity-Associated Gene)		A			
WHAT YOUR GENETICS SAY					
					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Lab ID	Gene	Allelic variants	Genotype		Result
Protein metabolism					
GTS003	MTHFR	C	C	C	FAVOURABLE
(metilen tetraidrofolato reduttasi)		T			
WHAT YOUR GENETICS SAY					
					
There is a FAVOURABLE genetic profile for the analyzed gene.					

EFFECTS OF VARIANTS IN THE ACTN3, FTO, AND MTHFR GENES

Unfavourable genetic variants in the ACTN3, FTO, and MTHFR genes can negatively impact protein metabolism, body composition, and physical performance.

ACTN3 – Impact on Muscle Strength and Power

- The unfavourable **ACTN3 gene variant** (R577X polymorphism) is associated with the absence of α-actinin-3, a protein essential for fast-twitch muscle fibres.

  Negative effects:

  - Reduced ability to develop explosive strength and muscle power, particularly important for speed and power sports like sprinting and weightlifting.
  - Increased susceptibility to muscle injuries and early fatigue.
  - Metabolic preference for endurance activities rather than power-based exercises.

FTO – Influence on Body Composition and Appetite

- The **FTO gene** regulates appetite, energy metabolism, and protein synthesis. Unfavourable variants are linked to increased fat accumulation and decreased lean muscle mass.

  Negative effects:

  - Greater tendency to accumulate fat and difficulty managing weight.
  - Altered appetite regulation, leading to increased hunger and cravings for carbohydrate- and fat-rich foods.
  - Reduced protein synthesis efficiency, which can impact muscle maintenance.

MTHFR – Effects on Protein Metabolism

- The **MTHFR gene** encodes a protein involved in homocysteine and folate metabolism, both of which are crucial for amino acid synthesis and DNA repair. The variant linked to high homocysteine levels negatively impacts protein metabolism, inflammation, and DNA integrity.
- Folate deficiency caused by MTHFR variants can lead to dysfunctions in protein metabolism and folic acid homeostasis, interfering with protein synthesis and repair.

Recommended Solutions

If genetic testing reveals unfavourable variants in the ACTN3, FTO, and MTHFR genes, specific strategies can be implemented to mitigate negative effects and improve protein metabolism, body composition, and physical performance.

For Unfavorable ACTN3 Variant:

- **Targeted Training**: Focus on strength and endurance exercises such as weight training, plyometrics, and short sprints to stimulate fast-twitch muscle fibres.
- **Enhanced Recovery**: Incorporate stretching, foam rolling, and proper rest to minimize injury risk.
- **Optimized Protein Nutrition**: Prioritize high-quality proteins (lean meat, fish, eggs, whey protein) to support muscle synthesis.

- **Recommended Supplementation**: Consider essential amino acids (BCAAs) and creatine monohydrate to enhance muscle performance.

For Unfavorable FTO Variant:

- **Balanced, Low-Calorie Diet**: Focus on a diet rich in protein and fibre to promote satiety and manage calorie intake.
- **Limit Sugars and Refined Carbs**: Reduce consumption of high glycemic index foods to prevent fat accumulation.
- **Combined Training**: Integrate strength training with HIIT (High-Intensity Interval Training) to boost metabolism and preserve lean mass.
- **Stress and Sleep Management**: Ensure adequate rest and manage stress levels to mitigate the impact of the FTO variant on fat storage.
- **Recommended Supplementation**: Supplement with green tea extract (EGCG), conjugated linoleic acid (CLA), and omega-3 to support weight management.

For Unfavorable MTHFR Variant:

- **Optimize Folate and B Vitamin Intake:**
  - The C677T variant of MTHFR reduces the efficiency of folate conversion. Consume folate-rich foods like green leafy vegetables, legumes, citrus fruits, and whole grains, and consider active folate supplements (5-MTHF).
  - Ensure adequate B6 and B12 intake as these vitamins are vital for amino acid metabolism.
- **Support Methionine and Homocysteine Metabolism:**
  - Increase intake of methionine-rich foods such as meat, fish, eggs, legumes, and seeds.
  - Supplement with B6, B12, and active folate to enhance methionine and homocysteine metabolism.
- **Maintain Antioxidant Balance:**
  - Incorporate antioxidant-rich foods like berries, citrus fruits, and green leafy vegetables to reduce oxidative stress and protect protein integrity.
  - Consider supplementing with vitamin C, vitamin E, selenium, and CoQ10.
- **Manage Inflammation Levels:**
  - Eat anti-inflammatory foods such as fatty fish, flaxseeds, walnuts, turmeric, and green tea to reduce chronic inflammation.
  - Supplement with omega-3 (EPA and DHA), curcumin, and vitamin D to improve the inflammatory response.
- **Limit Caffeine and Alcohol Intake:**
  - Excessive caffeine and alcohol can disrupt homocysteine metabolism. Limit these substances to maintain optimal protein balance and nutrient metabolism.
- **Regular Homocysteine Monitoring:**
  - Since the MTHFR variant can elevate homocysteine levels, monitor these levels regularly through blood tests, particularly if you have a family history of cardiovascular disease or other metabolic conditions.

In conclusion, despite the presence of unfavourable genetic variants, it is possible to optimize nutrition, training, and lifestyle to compensate for potential disadvantages, enhancing both physical performance and body composition.

4. TEST FOR CAFFEINE METABOLISM

Genetic analysis of the **CYP1A2 gene** focuses on variations that affect how the body metabolizes caffeine. The CYP1A2 gene encodes an enzyme in the liver responsible for breaking down caffeine.

Genetic variants of **CYP1A2** determine whether an individual is:

- **Fast metabolizer**: Caffeine is processed and eliminated quickly, resulting in fewer prolonged effects.
- **Slow metabolizer**: Caffeine remains in the body for a longer time, increasing the risk of side effects such as insomnia or hypertension.

This analysis helps customize caffeine intake based on one's genetic profile, optimizing both well-being and performance.

YOUR RESULT:

Lab ID	Gene	Allelic variants	Genotype		Metabolism
CAFFEINE METABOLISM					
GTS008	CYP1A2	A	A	A	RAPID CAFFEINE METABOLIZER
(cytochrome p450 isoform 1A2)		C			
WHAT YOUR GENETICS SAY					
There is a FAVOURABLE genetic profile for the analyzed gene.					

Effects of the Unfavourable Variant in the CYP1A2 Gene

1. **Prolonged Caffeine Accumulation**: Caffeine stays in the body for a longer period, increasing the likelihood of side effects.
2. **Increased Sensitivity to Caffeine**: Even small amounts of caffeine can lead to anxiety, insomnia, nervousness, and palpitations.
3. **Increased Cardiovascular Risk**: Research suggests that individuals with slower caffeine metabolism may have an elevated risk of hypertension and heart attacks with excessive caffeine intake.
4. **Sleep Disturbances**: Since caffeine is eliminated more slowly, it can interfere with sleep quality, particularly if consumed in the afternoon or evening.
5. **Reduced Sports Performance**: Slow caffeine metabolism may diminish its ergogenic effects, such as improved endurance and concentration, compared to fast metabolizers.

Recommended Solutions:

If genetic testing reveals slower caffeine metabolism due to unfavourable CYP1A2 variants, the following strategies can help minimize negative effects and optimize well-being:

1. **Limit Caffeine Intake**:
   - Consume no more than 200 mg of caffeine per day (approximately 1-2 cups of coffee) to avoid caffeine build-up and related symptoms like anxiety, insomnia, and palpitations.
   - Opt for low-caffeine alternatives, such as green tea, white tea, or decaffeinated coffee.
2. **Avoid Caffeine in the Afternoon and Evening**:
   - As caffeine is metabolized more slowly, refrain from consuming it at least 6-8 hours before bedtime to prevent sleep disturbances.

3. **Monitor Personal Response**:
    - Pay attention to how your body reacts to caffeine and adjust consumption based on symptoms (e.g., reduce intake further if you experience tachycardia or insomnia).
4. **Balance Diet and Hydration**:
    - Increase water intake to help flush caffeine out of your system.
    - Maintain a balanced diet rich in antioxidants (fruits, vegetables, omega-3) to counteract any oxidative stress caused by caffeine.
5. **Consider Alternative Energy Sources**:
    - For focus and energy without overloading the nervous system, try natural alternatives such as L-theanine (found in green tea), ginseng, or rhodora.

By adopting these strategies, you can better manage caffeine sensitivity and reduce the risk of side effects related to slower caffeine metabolism.

Final Conclusions:

Determining the ideal macronutrient (macro) intake involves finding the right balance of carbohydrates, proteins, and fats tailored to your goals, lifestyle, and genetics.

Macro Ratios Based on Goals:

- **Weight Loss**: Higher protein intake with moderate or low carbohydrates helps promote fat loss while maintaining muscle mass.
- **Increased Muscle Mass**: Higher protein intake and increased calories, often with moderate to high carbohydrates, support muscle growth.
- **Maintenance**: A balanced approach to maintain current weight and energy levels.

Common macro ratios include:

- **Balanced (Maintenance)**: 40% Carbs, 30% Protein, 30% Fat
- **Fat Loss (Low-Carb)**: 25% Carbs, 40% Protein, 35% Fat
- **Muscle Gain (High-Carb)**: 50% Carbs, 25% Protein, 25% Fat
- **Keto (Very Low-Carb)**: 5-10% Carbs, 20-25% Protein, 70-75% Fat

Everyone metabolizes macronutrients differently. The **MacroMatch genetic test** helps personalize your macronutrient ratio and offers guidance on your ideal caffeine consumption.

BIBLIOGRAPHY

ACTN3

1. Effective utilization of genetic information for athletes and coaches: focus on ACTN3 R577X polymorphism. Kikuki N, Nakazato K. J Exerc Nutr Biochem 2015. 19(3): 157-164
2. ACTN3 R577X and ACE I/D gene variants influence performance in elite sprinters: a multi-cohort study 2016. BMC Genomics 17:285. Papadimitriou ID.

MTHFR

1. Marini NJ, Gin J, Ziegle J, Keho KH, Ginzinger D, Gilbert DA, Rine J (2008) The prevalence of folate-remedial MTHFR enzyme variants in humans. *Proc Natl Acad Sci U S A* 105: 8055-8060.
2. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, S (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet* 376: 180-188.
3. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter D (2010) Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19: 2739-2745.
4. Zhi Luo, Zhan Lu, Irfan Muhammad, Yun Chen, Qiuhong Chen, Jiaojiao Zhang, Yongyan Song. Lipids Health Dis (2018). Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: a systematic review and updated meta-analysis.
5. Wei Zhang, Ye Wang, Guorong Bi. Cell Biochem Biophys (2015). Quantitative assessment of association between rs1801133 polymorphism and susceptibility to stroke.

FTO

1. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ne (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316: 889-894.
2. Sallman Almen M, Rask-Andersen M, Jacobsson JA, Ameur A, Kalnina I, Moschonis G, Juhlin S, Bringeland N, Hedberg LA, Ignatovica V, Chrousos GP, Manios Y, Klovins J, Marcus C, Gyllensten U, Fredriksson R, Schioth (2012) Determination of the obesity-associated gene variants within the entire FTO gene by ultra-deep targeted sequencing in obese and lean children. LID - 10.1038/ijo.2012.57 [doi]. Int J Obes (Lond).
3. Moleres A, Ochoa MC, Rendo-Urteaga T, Martinez-Gonzalez MA, Azcona San JuM, Martinez JA, Marti A, CN - G (2012) Dietary fatty acid distribution modifies obesity risk linked to the rs9939609 polymorphism of the fat mass and obesity-associated gene in a Spanish case-control study of children. Br J Nutr 107: 533-538.
4. Gonzalez JR, Gonzalez-Carpio M, Hernandez-Saez R, Serrano Vargas V, Torres Hidalgo G, Rubio-Rodrigo M, Garcia-Nogales A, Nunez Estevez M, Luengo Perez LM, Rodriguez-Lopez R (2012) FTO risk haplotype among early onset and severe obesity cases in a population of western Spain. Obesity (Silver Spring) 20: 909-15 LID - 10.1038/oby.
5. Wang H, Dong S, Xu H, Qian J, Yang J 2012 Genetic variants in FTO associated with metabolic syndrome: a meta- and gene-based analysis. Mol Biol Rep 39: 5691-5698

LIPID METABOLISM

1. Robin PFD., Sabrina P., Frank Gp. and Nicolas V. (2019) Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 20, 732.
2. Haochang H., Tian S., Jun M., Ruoyu C., Jian W., Shuangshuang W., Shaoyi L. and Xiaomin C. (2021) Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia. Frontiers in Genetics 12:762587.
3. Chao-Qiang l., Parnell LD., Ordovas JM. (2005) The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Current Opinion in Lipidology 16(2):153-166.
4. Dybiec J., Baran W., Dabek B., Fularski P., Młynarska E., RadziochE., Rysz J. and Franczyk B. (2023) Advances in Treatment of Dyslipidemia. Int. J. Mol. Sci. 24, 13288.
5. Xin S. and Daoquan P. (2020) The exchangeable apolipoproteins in lipid metabolism and obesity. Clin Chim Acta 503:128-135.
6. Rouland A., Masson D., Lagrost L., Vergès B., Gautier T. and Bouillet B. (2022) Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes a systematic review. Cardiovascular Diabetology 21:272.

CARBOHYDRATE METABOLISM

1. Raphael ET., Henry B., Dharleen RC., Willie ME., Clarisse AS., Engracia Ar. (2023) Association of the rs3856806 Polymorphism in the PPARG Gene with Type 2 Diabetes Mellitus: A Meta-Analysis of 11,811 Individuals. Lab Med 54(2):193-198.
2. Junyan L., Xiaohong N., JianBo L., Qingzhong W. (2019) Association of PPARG Gene Polymorphisms Pro12Ala with Type 2 Diabetes Mellitus: A Meta-analysis.15(4):277-283.
3. Polin H, Zahurin M., Nor A., Pantea H., Monir SH, and Batoul SH (2015) KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus. Review Article Journal of Diabetes Research.
4. Negar S., Farshad S., Leila H., Maryam HD, Katayoun H., Marzieh R., Seyed HJ., Hamid RAM, & Mandana H. (2020) PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. Nature research 10:12764.
5. Yu T., Ying L., Yuan Z., Jiyun Y., Yawei Z., Hengchuan L., and Ben Z. (2009) Association between TCF7L2 gene polymorphisms and susceptibility to Type 2 Diabetes Mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Medical Genetics 10:15.
6. Sara KH., Eva-Maria DN., Jakob E., Gitte A., Charlotte G., Bendix C., Peter M., Thomas D., Knut BJ., Torben J., Torben H., Oluf P. (2005) Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes. J Clin Endocrinol Metab 90: 3629-3637.

CAFFEINE

1. Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, Papparella I, Mos L, Zanata G, Santonastaso M (2009) CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 27: 1594-1601.
2. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C to A polymorphism in intron 1 of thecytochrome P450 1A2 (CYP1A2) gene tested with caffeine. Br J Clin Pharmacol 1999; 47:445-449.
3. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, et al. (2001) Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734 polymorphisms of human CYP1A2. Pharmacogenetics; 11:429 - 435.